ESAs not the culprit: More studies required

American Journal of Hematology

Volumn 83, Issue 11, 2008, Pages 880-

  Ludwig, Heinz ^a   Anderson, Kenneth ^b   Dammacco, Franco ^c   Hedenus, Michael ^d   Osterborg, Anders ^e   Durie, Brian ^f,g  

^a WILHELMINEN HOSPITAL   (Austria)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^d SUNDSVALL HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g Aptium Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; CREATININE; ERYTHROPOIETIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; SERUM ALBUMIN;

ALBUMIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CREATININE BLOOD LEVEL; DRUG EFFICACY; GROUPS BY AGE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LETTER; MULTIPLE MYELOMA; PARAPROTEINEMIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ANEMIA; COHORT STUDIES; HEMATINICS; HUMANS; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 55549147560     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21270     Document Type: Letter

References (3)

1. Katodritou E, Verrou E, Hadjiaggelidou C, et al. Erythropoiesis stimulating agents are associated with reduced survival in patients with multiple myeloma. Am J Hematol 2008. [Epub ahead of print].
2. Rothman K, Greenland S, Lash T, editors. Modern Epidemiology, third edition. Philadelphia: Lippincott, Williams & Wilkins; 2008. p 650.
3. Baz R, Walker E, Choueiri TK, et al. Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematol 2007;117:162-167.